Singapore-based investment firm Temasek infuses over Rs 690 crore in Molbio Diagnostics

Published On 2022-09-28 08:30 GMT | Update On 2022-09-29 05:12 GMT

New Delhi: Healthcare solutions provider Molbio Diagnostics on Monday said Singapore-based investment firm Temasek has invested USD 85 million (over Rs 690 crore) in the company. Goa-based Molbio Diagnostics is known for its 'Truenat' technology -- a portable, battery-operated real-time PCR platform that can be used for testing infectious diseases, including TB, COVID-19, Hepatitis-C virus, human papillomavirus, influenza and vector-borne diseases like dengue, chikungunya and malaria.

The fresh funds from Temasek along with those from existing investors such as Motilal Oswal Alternates, will help the company accelerate development and commercialisation of new technologies based on clinical need gaps, Molbio Diagnostics said in a statement.

This will also help the company in fast-tracking its efforts to take the Truenat platform to global markets, it added.

"The demand for high-quality, point-of-care molecular diagnostic systems is higher than ever today. The strategic partnership with Temasek will strengthen our ability to provide sustainable choices to address global healthcare challenges," Molbio Diagnostics Director and CEO, Sriram Natarajan said.

Molbio Diagnostics said its Truenat real-time PCR has been deployed in over 5,000 testing centers across over 40 countries around the world.

In India, the government has deployed these devices at primary and community health centers across all states and Union Territories under the National Tuberculosis Elimination Program, it added.

"Over the past three years, Molbio has changed the diagnostic paradigm across India and has had a real impact in saving millions of lives," Motilal Oswal Alternates Director Rohit Mantri said.

Motilal Oswal Alternates had associated with Molbio just few months prior to the COVID-19 pandemic, "when the requirement of capital was extremely critical, and something that led to Molbio playing a very important role in ramping up of the testing infrastructure in India," he added.

Molbio Diagnostics said its Truenat portable technology platform enables early and accurate diagnosis of infectious diseases and initiation of correct treatment right at the first point of contact and can be deployed at all levels of the healthcare chain, including very remote and inaccessible areas.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Singapore-based investment firm Temasek infuses over Rs 690 crore in Molbio Diagnostics

Similar News

Setback To Novartis: CDSCO Panel Rejects Lanalumab Phase III Trial Design Over Study Flaws

Kerala Medical Services Corporation not procured rabies vaccine without CDL certificate: Health Minister

37 Essential Drugs Including Paracetamol, Atorvastatin To Get Cheaper, NPPA Issues Revised Price List

Over 5 lakh Tramadol, Alprazolam tablets worth Rs 20 crore seized,; 5 arrested

Roche Susvimo maintains vision over five years with two refills per year in people with nAMD

Fire erupts at Dey's Medical plant in Kolkata, no injuries reported

One-shot Dengue vaccine 'DengiAll' completes 70% enrolment of participants in Phase III trial: Centre

Sun Pharma Gets Relief As Delhi HC Bars Use of BERIVITAL, BEZOLIC, DOZE-30 For Trademark Infringement